DNA repair mechanisms in colorectal carcinogenesis

Current Molecular Medicine

Volumn 12, Issue 3, 2012, Pages 237-246

  Michailidi, C ^a   Papavassiliou, A G ^a   Troungos, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Biomarker; Colorectal carcinogenesis; DNA repair; Gene polymorphism; Genetic instability; Genetic predisposition

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA; FLUOROURACIL; FOLINIC ACID; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; IRINOTECAN; OXALIPLATIN;

APOPTOSIS; ARTICLE; CANCER RISK; CARCINOGENESIS; CHROMOSOME ABERRATION; COLORECTAL CANCER; COLORECTAL CARCINOGENESIS; DNA REPAIR; EXCISION REPAIR; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC RECOMBINATION; HUMAN; MISMATCH REPAIR; NONHUMAN;

ANIMALS; COLORECTAL NEOPLASMS; DNA REPAIR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84857133220     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412799218859     Document Type: Article

References (121)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
3. Gervaz P, Bouzourene H, Cerottini JP, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 2001; 44: 364-372.
4. Miyakura Y, Sugano K, Konishi F, et al. Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology 2001; 121: 1300-1309.
5. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-819.
6. Delattre O, Olschwang S, Law DJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989; 334: 353-356.
7. Patchett SE, Alstead EM, Saunders BP, Hodgson SV, Farthing MJ. Regional proliferative patterns in the colon of patients at risk for hereditary nonpolyposis colorectal cancer. Dis Colon Rectum 1997; 40: 168-171.
8. Friedberg EC, McDaniel LD, Schultz RA. The role of endogenous and exogenous DNA damage and mutagenesis. Curr Opin Genet Dev 2004; 14: 5-10.
9. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374.
10. Pecorino L. Molecular biology of cancer: Mechanisms, targets, and therapeutics, 1rst ed. New York: Oxford University Press 2005.
11. Sancar A. Structure and function of DNA photolyase and cryptochrome blue-light photoreceptors. Chem Rev 2003; 103: 2203-2237.
12. Lindahl T. Suppression of spontaneous mutagenesis in human cells by DNA base excision-repair. Mutat Res 2000; 462: 129-135.
13. Nilsen H, Krokan HE. Base excision repair in a network of defense and tolerance. Carcinogenesis 2001; 22: 987-998.
14. Krokan HE, Nilsen H, Skorpen F, Otterlei M, Slupphaug G. Base excision repair of DNA in mammalian cells. FEBS Lett 2000; 476: 73-77.
15. Memisoglu A, Samson L. Base excision repair in yeast and mammals. Mutat Res 2000; 451: 39-51.
16. Frosina G, Fortini P, Rossi O, et al. Two pathways for base excision repair pathways in mammalian cells. J Biol Chem 1996; 271: 9573-9578.
17. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001; 1: 22-33.
18. Paques F, Haber JE. Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 1999; 63: 349-404.
19. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis 2002; 23: 687-696.
20. Thompson LH, Schild D. Recombinational DNA repair and human disease. Mutat Res 2002; 509: 49-78.
21. Collis SJ, DeWeese TL, Jeggo PA, Parker AR. The life and death of DNA-PK. Oncogene 2005; 24: 949-961.
22. Evans E, Alani E. Roles for mismatch repair factors in regulating genetic recombination. Mol Cel Biol 2000; 20: 7839-7844.
23. Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev 1999; 9: 89-96.
24. Buermeyer AB, Deschenes SM, Baker SM, Liskay RM. Mammalian DNA mismatch repair. Annu Rev Genet 1999; 33: 533-564.
25. Marti TM, Kunz C, Fleck O. DNA mismatch repair and mutation avoidance pathways. J Cell Physiol 2002; 191: 28-41.
26. Harfe BD, Jinks-Roberton S. DNA mismatch repair and genetic instability. Annu Rev Genet 2000; 34: 359-399.
27. Hsieh P. Molecular mechanisms of DNA mismatch repair. Mutat Res 2001; 486: 71-87.
28. Acharya S, Wilson T, Gradia S, et al. HMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 1996; 93: 13629-13634.
29. Gatzidou E, Michailidi C, Tseleni-Balafouta S, Theocharis S. An epitome on DNA repair related genes and mechanisms in thyroid carcinoma. Cancer Lett 2010; 290: 139-147.
30. Nguyen H, Loustaunau C, Facista A, et al. Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancer. J Vis Exp 2010; 41. pii: 1931.
31. Stern MC, Butler LM, Corral R, et al. Polyunsaturated fatty acids, DNA repair single nucleotide polymorphisms and colorectal cancer in the Singapore Chinese Health Study. J Nutrigenet Nutrigenomics 2009; 2: 273-279.
32. Egly JM. The 14th Datta Lecture TFIIH: from transcription to clinic. FEBS Lett 2001; 498: 124-128.
33. Weeda G, Hoeijmakers JH. Genetic analysis of nucleotide excision repair in mammalian cells. Semin Cancer Biol 1993; 4: 105-117.
34. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998; 58: 604-608.
35. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61: 1354-1357.
36. Qiao Y, Spitz MR, Guo Z, et al. Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. Mutat Res 2002; 509: 165-174.
37. Moller P, Knudsen LE, Frentz G, Dybdahl M, Wallin H, Nexo BA. Seasonal variation of DNA damage and repair in patients with non-melanoma skin cancer and referents with and without psoriasis. Mutat Res 1998; 407: 25-34.
38. Wang J, Zhao Y, Jiang J, et al. Polymorphisms in DNA repair genes XRCC1, XRCC3 and XPD, and colorectal cancer risk: a case-control study in an Indian population. J Cancer Res Clin Oncol 2010; 136: 1517-1525.
39. Mort R, Mo L, McEwan C, Melton DW. Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer 2003; 89: 333-337.
40. Skjelbred CF, Saebo M, Wallin H, et al. Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study. BMC Cancer 2006; 6: 67.
41. Yeh CC, Hsieh LL, Tang R, Chang-Chieh CR, Sung FC. MS- 920: DNA repair gene polymorphisms, diet and colorectal cancer risk in Taiwan. Cancer Lett 2005; 224: 279-288.
42. Stern MC, Conti DV, Siegmund KD, et al. DNA repair singlenucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2363-2372.
43. Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000; 21: 551-555.
44. Xiang DB, Chen ZT, Wang D, et al. Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer Gene Ther 2008; 15: 625-635.
45. Hollander MC, Alamo I, Jackman J, Wang MG, McBride OW, Fornace AJ. Analysis of the mammalian gadd45 gene and its response to DNA damage. J Biol Chem 1993; 268: 24385-24393.
46. Jung HJ, Kim EH, Mun JY, et al. Base excision DNA repair defect in Gadd45a-deficient cells. Oncogene 2007; 26: 7517-7525.
47. Caldecott KW, McKeown CK, Tucker JD, Ljungquist S, Thompson LH. An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. Mol Cell Biol 1994; 14: 68-76.
48. Gryk MR, Marintchev A, Maciejewski MW, Robertson A, Wilson SH, Mullen GP. Mapping of the interaction interface of DNA polymerase beta with XRCC1. Structure 2002; 10: 1709-1720.
49. Whitehouse CJ, Taylor RM, Thistlethwaite A, et al. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell 2001; 104: 107-117.
50. Vidal AE, Boiteux S, Hickson ID, Radicella JP. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J 2001; 20: 6530-6539.
51. Slupska MM, Luther WM, Chiang JH, Yang H, Miller JH. Functional expression of hMYH, a human homolog of the Escherichia coli MutY protein. J Bacteriol 1999; 181: 6210-6213.
52. Ohtsubo T, Nishioka K, Imaiso Y, et al. Identification of human MutY homolog (hMYH) as a repair enzyme for 2- hydroxyadenine in DNA and detection of multiple forms of hMYH located in nuclei and mitochondria. Nucleic Acids Res 2000; 28: 1355-1364.
53. Takao M, Zhang QM, Yonei S, Yasui A. Differential subcellular localization of human MutY homolog (hMYH) and the functional activity of adenine:8-oxoguanine DNA glycosylase. Nucleic Acids Res 1999; 27: 3638-3644.
54. Hirano S, Tominaga Y, Ichinoe A, et al. Mutator phenotype ofMUTYH-null mouse embryonic stem cells. J Biol Chem 2003; 278: 38121-38124.
55. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet 2002; 30: 227-232.
56. Jones S, Emmerson P, Maynard J, et al. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C→T:A mutations. Hum Mol Genet 2002; 11: 2961-2967.
57. Sieber O M, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003; 348: 791-799.
58. Halford SE, Rowan AJ, Lipton L, et al. Germline mutations but not somatic changes at the MYH locus contribute to the pathogenesis of unselected colorectal cancers. Am J Pathol 2003; 162: 1545-1548.
59. Enholm S, Hienonen T, Suomalainen A, et al. Proportion and phenotype of MYH-associated colorectal neoplasia in a population-based series of Finnish colorectal cancer patients. Am J Pathol 2003; 163: 827-832.
60. Lipton L, Halford S E, Johnson V, et al. Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. Cancer Res 2003; 63: 7595-7599.
61. Fleischmann C, Peto J, Cheadle J, Shah B, Sampson J, Houlston RS. Comprehensive analysis of the contribution of germline MYH variation to early-onset colorectal cancer. Int J Cancer 2004; 109: 554-558.
62. Parker AR, Sieber OM, Shi C, et al. Cells with pathogenic biallelic mutations in the human MUTYH gene are defective in DNA damage binding and repair. Carcinogenesis 2005; 26: 2010-2018.
63. Guan Y, Manuel RC, Arvai AS, et al. MutY catalytic core, mutant and bound adenine structures define specificity for DNA repair enzyme superfamily. Nat Struct Biol 1998; 5: 1058-1064.
64. Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 1999; 401: 301-304.
65. Bellacosa A, Cicchillitti L, Schepis F, et al. MED1, a novel human methyl CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proc Natl Acad Sci USA 1999; 96: 3969-3974.
66. Howard JH, Frolov A, Tzeng CDW, et al. Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer. Cancer Biol Ther 2009; 8: 1-7.
67. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7- hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997; 57: 4029-4035.
68. Yu Q, Rose JH, Zhang H, Pommier Y. Antisense inhibition of Chk2/ hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK- 293 cells. FEBS Lett 2001; 505: 7-12.
69. Chehab NH, Malikzay A, Appel M, Halazonetis TD. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 2000; 14: 278-288.
70. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15: 2177-2196.
71. Mailand N, Falck J, Lukas C, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000; 288: 1425-1429.
72. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277: 1501-1505.
73. Ahn JY, Schwarz JK, Piwnica-Worms H, Canman CE. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizingradiation. Cancer Res 2000; 60: 5934-5936.
74. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429.
75. Ghosh JC, Dohi T, Raskett CM, Kowalik TF, Altieri DC. Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res 2006; 66: 11576-11579.
76. Zhuang J, Zhang J, Willers H, et al. Checkpoint kinase 2- mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous endjoining. Cancer Res 2006; 66: 1401-1408.
77. Huang M, Miao ZH, Zhu H, Cai YJ, Lu W, Ding J. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Therap 2008; 7: 1440-1449.
78. Stawinska M, Cygankiewicz A, Trzcinski R, Mik M, Dziki A, Krajewska WM. Alterations of Chk1 and Chk2 expression in colon cancer. Int J Colorect Dis 2008; 23: 1243-1249.
79. Brenneman MA, Weiss AE, Nickolo VJA, Chen DJ. XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. Mutat Res 2000; 459: 89-97.
80. Stern MC, Umbach DM, Lunn RM, Taylor JA. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 939-943.
81. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999; 13: 2633-2638.
82. Griffin CS. Aneuploidy, centrosome activity and chromosome instability in cells deficient in homologous recombination repair. Mutat Res 2002; 504: 149-155.
83. Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32) P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001b; 22: 1437-1445.
84. Jin MJ, Chena K, Songa L, et al. The association of the DNA repair gene XRCC3 Thr241Met polymorphism with susceptibility to colorectal cancer in a Chinese population. Cancer Gen Cytogen 2005; 163: 38-43.
85. Kanaar R, Troelstra C, Swagemakers SM, et al. Human and mouse homologs of the Saccharomyces cerevisiae RAD54 DNA repair gene: evidence for functional conservation. Curr Biol 1997; 6: 828-838.
86. Takata M, Sasaki MS, Sonoda E, et al. Homologous recombination and nonhomologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 1998; 17: 5497-5508.
87. Miyagawa K, Tsuruga T, Kinomura A, et al. A role for RAD54B in homologous recombination in human cells. EMBO J 2002; 21: 175-180.
88. Hiramoto T, Nakanishi T, Sumiyoshi T, et al. Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. Oncogene 1999; 18: 3422-3426.
89. Cartwright R, Tambini CE, Simpson PJ, Thacker J. The XRCC2 DNA repair gene from human and mouse encodes a novel member of the recA/RAD51 family. Nucleic Acids Res 1998; 26: 3084-3089.
90. Curtin K, Lin WY, George R, et al. Genetic variants in XRCC2: new insights into colorectal cancer tumorigenesis. Cancer Epidemiol Biomarkers Prev 2009; 18: 2476-2484.
91. Edelmann L, Edelmann W. Loss of DNA mismatch repair function and cancer predisposition in the mouse: animal models for human hereditary nonpolyposis colorectal cancer. Am J Med Genet 2004; 129C: 91-99.
92. Liu HX, Zhou XL, Liu T, et al. The role of hMLH3 in familial colorectal cancer. Cancer Res 2003; 63: 1894-1899.
93. Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004; 4: 769-780.
94. Liu B, Parsons R, Papadopoulos N, et al. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 1996; 2: 169-174.
95. Chen PC, Dudley S, Hagen W, et al. Contributions by MutLhomologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse. Cancer Res 2005; 65: 8662-8670.
96. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. Chem Rev 2006; 106: 302-323.
97. Yu JH, Bigler J, Whitton J, Potter JD, Ulrich CM. Mismatch repair polymorphisms and colorectal polyps: hMLH1293G>A variant modifies risk associated with smoking. Am J Gastroenterol 2006; 101: 1313-1319.
98. Raptis S, Mrkonjic M, Green RC, et al. MLH1293G>A promoter polymorphism and the risk of microsatelliteunstable colorectal cancer. J Natl Cancer Inst 2007; 99: 463-474.
99. Allan JM, Shorto J, Adlard J, et al. MLH1 293G>A promoterpolymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer 2008; 123: 2456-2459.
100. Gibson SL, Narayanan L, Hegan DC, Buermeyer AB, Liskay RM, Glazer PM. Over expression of the DNA mismatch repair factor, PMS2, confers hypermutability and DNA damage tolerance. Cancer Lett 2006; 244: 195-202.
101. Boland CR, Goel A. Micro satellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-2087.
102. Iacopetta B, Grieu F, Amanuel B. Microsatellite instability in colorectal cancer. Asia Pac J Clin Oncol 2010; 6: 260-269.
103. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010; 7: 153-162.
104. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumor site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355: 1745-1750.
105. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
106. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-4886.
107. Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997; 57: 1841-1845.
108. Kim ST, Lee J, Park SH. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010; 66: 659-667.
109. Fallik D, Borrini F, Boige V, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003; 63: 5738-5744.
110. Poynter JN, Siegmund KD, Weisenberger DJ, et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 2008; 17: 3208-3215.
111. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4: 1-6.
112. Yang JL, Qu XJ, Yu Y, Kohn EC, Friedlander ML. Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. Int J Cancer. 2008; 123: 258-263.
113. Kohn EC, Liotta LA. L651582: a novel antiproliferative and antimetastasis agent. J Natl Cancer Inst 1990; 82: 54-60.
114. Kohn EC, Felder CC, Jacobs W, et al. Structurefunction analysis of signal and growth-inhibition by carboxyamidotriazole, CAI. Cancer Res 1994; 54: 935-942.
115. Hupe DJ, Boltz R, Cohen CJ, et al. The inhibition of receptormediated and voltagedependent calcium entry by the antiproliferative L-65 1582. J Biol Chem 1991; 266: 10136-10142.
116. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy. J Natl Cancer Inst 2011; 103: 863-875.
117. Li LS, Morales JC, Veigl M, et al. DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol 2009; 158: 679-692.
118. Martin SA, McCarthy A, Barber LJ, et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair geneMSH2. EMBO Mol Med 2009; 1: 323-337.
119. Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005; 53: 3-11.
120. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24: 331-344.
121. Balin-Gauthier D, Delord JP, Pillaire MJ, et al. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 2008; 98:120-128.